

# **Anti-Progesterone Receptor (InSite® PR)** [PR88]

Catalog No.	Description		
AM328-5M	6 ml of Ready-to-Use Antibody for use with BioGenex Super Sensitive <sup>TM</sup> Detection Systems OR equivalent detection system		
AM328-10M	10 ml of Ready-to-Use Antibody in a barcode labeled vial for use with BioGenex Super Sensitive <sup>TM</sup> Detection Systems and i6000 <sup>TM</sup> Automated Staining Systems		
MU328-UC	1 ml of Concentrated Antibody for use with BioGenex Super Sensitive <sup>TM</sup> Detection Systems OR equivalent detection system		
MU328-5UC	0.5 ml of Concentrated Antibody for use with BioGenex Super Sensitive TM Detection Systems OR equivalent detection system		
AX328-YCD	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 160 tests		
AX328-50D	Ready-to-Use Antibody in Barcode labeled vial for use on the Xmatrx® Elite/Ultra Staining System, 50 tests		

Clone	Species	Ig Class
PR88	Mouse	IgG1, kappa

# **Intended Use**

For In Vitro Diagnostic Use. This antibody is designed for the specific localization of Progesterone Receptor in formalin-fixed, paraffin-embedded (FFPE) tissue sections. Evaluation must be performed by a qualified pathologist.

#### **Summary and Explanation**

The use of monoclonal antibodies to determine progesterone receptor status increases the predictive value immunohistochemical analysis with respect to the response of human tumors to hormonal modulation. Historically, estrogen receptor-positive/progesterone receptor-positive carcinoma patients have demonstrated a better response to endocrine therapy than estrogen receptor-positive/ progesterone receptornegative patients.

#### **Storage and Handling**

Store at 2-8°C. Fresh dilutions, if required, should be prepared prior to use and are stable and steady for up to one day at room temperature (20-26°C). Diluted antibody preparations can be refrigerated or frozen for extended shelf life.

# **Principles of the Procedure**

Antigen detection by immunohistochemistry (IHC) is a two-step process wherein the primary antibody binds to the antigen of interest and that binding is detected by a chromogen. The primary antibody may be used in IHC using manual techniques or BioGenex Automated Staining System. Positive and negative controls should always be run simultaneously with all patient specimens.

# **Reagents Provided**

Mouse Monoclonal Antibody Progesterone Receptor is affinity purified and diluted in PBS, pH 7.2, containing 1% BSA and 0.09%

# **Dilution of Primary Antibody**

BioGenex Ready-to-Use antibodies have been optimized for use with the recommended BioGenex Detection System and should not require further dilution.

BioGenex concentrated antibodies must be diluted in accordance with the recommended protocol when used with the recommended BioGenex Detection System.

## **Recommended Protocol**

Refer to the following table for conditions specifically recommended for this antibody. Refer to the BioGenex website for guidance on specific staining protocols or other requirements.

Parameter	BioGenex Recommendations	
Control Tissue	Breast Cancer as available with Biogenex FB-328M* & FG-328M*	
Recommended Dilution for Concentrated Antibody	1:25-40 in HK156	
Recommended Pretreatment (Manual/i6000)**	EZ-AR2 (HK522-XAK)	
Recommended Pretreatment (Xmatrx)	EZ-AR2 Elegance (HX032-YCD)	
Antibody Incubation (Manual/i6000)	30-60 min at RT	
Antibody Incubation (Xmatrx)	30-60 min at 25°C	
Detection System for Manual, Xmatrx & i6000 systems***	Use BioGenex Two-Step <b>OR</b> One-Step Super Sensitive <sup>™</sup> Polymer-HRP IHC Detection System/DAB; see p. 2 for more information	

\*FB: positive control micro chamber slides, FG: positive control microscopic slides. Xmatrx requires micro chamber slides. \*\*Pretreatment times will vary based on individual microwave power. \*\*\*For automation systems (Xmatrx-Elite, Xmatrx-Ultra & i6000 Diagnostics), refer to the factory protocols provided with the instrument.

Category	Antibodies	Revision No.	G
Document No.	932-328M	Release Date	11-Jan-2022



	T	I -	I
Detection	Two-Step	One-Step	Link and
System	HRP Kit	HRP Kit	Label Kit
	QD440-XAKE		
	(1000 Test)	QD630-XAKE	QP300-XAKE
	QD430-XAKE	(1000 Test)	(1000 Test)
Manual	(1000 Test)		
Manuai	QD420-YIKE		
	(500 Test)	QD620-XAKE	QP900-9LE
	QD400-60KE	(500 Test)	(500 Test)
	(60 Test)		
Xmatrx -	QD550-YCDE	QD610-YADE	N/A
Automation	(200 Test)	(200 Test)	IN/A
i6000 -	QD410-YAXE	QD610-YAXE	N/A
Automation	(200 Test)	(200 Test)	IN/A

# For more information, visit www.biogenex.com.

#### **Precautions**

This product contains sodium azide at concentrations of less than 0.1%. Sodium azide is not classified as a hazardous chemical at the product concentrations, but proper handling protocols should be observed. For more information, a Safety Data Sheet (SDS) for sodium azide is available upon request. Dispose of unused reagents according to Local, State and Federal Regulations. Wear suitable Personal Protective Equipment, do not pipette reagents by mouth, and avoid contact of reagents and specimens with skin and mucous membranes. If reagents or specimens come in contact with sensitive area, wash with copious amounts of water.

# **Quality Control**

Refer to BioGenex detection system documents for guidance on general quality control procedures.

# **Troubleshooting**

Refer to the troubleshooting section in the documentation for BioGenex Detection Systems (or equivalent detection systems) for remedial actions on detection system related issues, or contact BioGenex Technical Support Department at 1-800-421-4149 or support@biogenex.com or your local distributor to report unusual staining.

# **Expected Results**

This antibody stains cytoplasm in positive cells in formalin-fixed, paraffin embedded tissue sections. An example image of a tissue section stained with this antibody can be found on the product page on the BioGenex website. Interpretation of the staining result is solely the responsibility of the user. Experimental results should be confirmed by a medically-established diagnostic product or procedure.

# Emergo Europe, Prinsessegracht 20, 2514AP The Hague, The Netherlands

### **Limitations of the Procedure**

Improper tissue handling and processing prior to immunostaining can lead to inconsistent results. Variations in embedding and fixation or the nature of the tissue may lead to variations in results. Endogenous peroxidase activity or pseudo peroxidase activity in erythrocytes and tissue biotin may result in non-specific staining based on the detection system employed. Tissues containing Hepatitis B Surface Antigen (HBsAg) may give false positive with horseradish peroxidase systems. Improper counterstaining and mounting may compromise the interpretation of results.

# **Bibliography**

- Carcangiu M L, et al. Am J Clin Pathol 94:247-254, 1990. 1.
- Logeat F, et al. Proc Natl Acad Sci USA 78:1426-1430,1981.
- 3. Perrot-Applantat M, et al. Cancer Research 47:2652-2262,1987.
- 4. Press MF, et al. Endocrionol 122:1165-1175, 1988. Reiner A, et al. Cancer Res 50:7057-7061, 1990.
- 5. Center for Disease Control. Decontamination of Laboratory Sink Drains to Remove Azide Salts. Center for Disease Control Manual Guide--Safety Management, No. CDC-22, Atlanta, Georgia. April 30, 1976.
- 6. Kiernan JA. Histological and Histochemical Methods: Theory and Practice. New York: Pergamon Press 1981.
- 7. Nadji M, Morales AR. Immunoperoxidase, part 1: the techniques and its pitfall. Lab Med 1983; 14:767-770.
- Omata M, Liew CT, Ashcavai M, Peters Rl. Nonimmunologic binding of horseradish peroxidase to hepatitis B surface antigen. A possible source of error in immunohistochemistry. Am J Clin Pathol. 1980:73(5):626-632.
- 9. U.S. Congress. Clinical Laboratory Improvement Amendments of 1988: Final Rule, 57 FR 7163, February 28, 1992.
- 10. National Institute for Occupational Safety and Health, (NIOSH), Rockville, MD. Explosive azide hazard, Publication No. 78-127, 1976.

2°C 8°C	Temperature Limitation	IVD	In Vitro Diagnostic Medical Device
$\boxtimes$	Use By Date	LOT	Batch Code
NON STERILE	Non-Sterile	[]i	Consult Instructions for Use
EC REP	Representative in the European Community	•••	Manufacturer

© 2020, BioGenex Laboratories. All rights reserved.

Category	Antibodies	Revision No.	G
Document No.	932-328M	Release Date	11-Jan-2022